An Update on Osteoporosis Pathogenesis, Diagnosis, and Treatment is an on-demand webcast CME activity. Osteoporosis is a serious health problem that is increasing with the growth of the aging population. Left untreated, patients with osteoporosis experience considerable morbidity and increased mortality, and their care exacts a large economic burden on the health care system. Although regularly updated clinical guidelines, risk assessment tools, and effective pharmacologic agents are available for the prevention and treatment of osteoporosis, data indicate that patients are not receiving the recommended level of care. In fact, the percentage of patients receiving osteoporosis treatment has declined in recent years even in those with hip fractures.
Diabetes & Endocrinology
Find out the latest in the world of diabetes & endocrinology by taking one of Elsevier's complimentary continuing medical education courses.
Insulin has been used as a standard treatment for patients with diabetes for almost 100 years. Over time, advances in insulin development have improved its pharmacologic properties. Most recently, the US Food and Drug Administration approved a novel, follow-on basal insulin agent, with more expected to be commercially available in the near future. With the imminent availability of follow-on basal insulin agents, clinicians need to be aware of the potential benefits and concerns in order to facilitate informed decision making and to provide the best possible advice and guidance to their patients with diabetes. This program will review how follow-on insulin products are developed, manufactured, and receive regulatory approval; evaluate clinical trial data for new and emerging follow-on basal insulin agents; and provide practical information and guidance on how they may be incorporated into clinical practice. While it is unknown how follow-on basal insulins will affect patient outcomes, they have the potential to increase access to treatment among patients with diabetes and reduce healthcare costs.